Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.
Aarne KolonenMarjatta SinisaloHeini HuhtalaJohanna RimpiläinenHannele RintalaMarja SankeloElli KoivunenRaija SilvennoinenRiikka RätyTapani RuutuLiisa VolinKimmo PorkkaEsa JantunenTapio NousiainenTaru KuittinenKarri PenttiläMarja PyöräläMarjaana SäilyPirjo KoistinenMarjut KauppilaMaija Itälä-RemesHanna OllikainenAuvo RauhalaVeli KairistoTarja-Terttu PelliniemiErkki Elonennull nullPublished in: European journal of haematology (2022)
Intensified cytarabine dose in the first induction treatment was not better than IAT in patients with AML. Intensification of postremission treatment in patients with clinical risk factors or MRD seems reasonable, but randomized controlled studies are warranted in the future.